HRMY (Harmony Biosciences Holdings, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by HRMY officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-18 | Linda M Szyper | Director | A | — | — |
| 2026-05-18 | Geno J Germano | Director | A | — | — |
| 2026-05-18 | Juan A. Sabater | Director | A | — | — |
| 2026-05-18 | Gary Sender | Director | A | — | — |
| 2026-05-18 | R. Mark Graf | Director | A | — | — |
| 2026-05-18 | Kumar Budur | CHIEF MEDICAL OFFICER | MIXED | — | — |
| 2026-05-18 | Ron M Philip | Director | A | — | — |
| 2026-05-18 | Glenn Reicin | CHIEF FINANCIAL OFFICER | A | — | — |
| 2026-04-09 | Adam H. Zaeske | CHIEF COMMERCIAL OFFICER | MIXED | — | — |
| 2026-04-06 | Peter Anastasiou | CHIEF OPERATING OFFICER | A | — | — |
| 2026-04-06 | Troy A. Ignelzi | Director | A | — | — |
| 2026-01-28 | Sandip Kapadia | CHIEF FINANCIAL OFFICER | Sell | — | — |
| 2026-01-26 | Adam H. Zaeske | CHIEF COMMERCIAL OFFICER | A | — | — |
| 2026-01-26 | Kumar Budur | CHIEF MEDICAL OFFICER | MIXED | — | — |
| 2026-01-26 | Sandip Kapadia | CHIEF FINANCIAL OFFICER | MIXED | — | — |
| 2026-01-26 | Andrew Serafin | CHIEF STRATEGY OFFICER | MIXED | — | — |
| 2026-01-26 | Jeffrey M. Dayno | PRESIDENT, CEO | MIXED | — | — |
| 2026-01-20 | Sandip Kapadia | CHIEF FINANCIAL OFFICER | Sell | — | — |
| 2025-12-17 | Jeffrey M. Dayno | PRESIDENT, CEO | MIXED | — | — |
| 2025-12-09 | Sandip Kapadia | CHIEF FINANCIAL OFFICER | MIXED | — | — |
| 2025-11-25 | Sandip Kapadia | CHIEF FINANCIAL OFFICER | Sell | — | — |
| 2025-10-02 | Sandip Kapadia | CHIEF FINANCIAL OFFICER | MIXED | — | — |
| 2025-09-02 | Valor Equity Capital IV LLC | 10%+ Owner | J | — | — |
| 2025-08-19 | Sandip Kapadia | CHIEF FINANCIAL OFFICER | Sell | — | — |
| 2025-05-16 | Peter Anastasiou | Director | A | — | — |
| 2025-05-16 | Linda M Szyper | Director | A | — | — |
| 2025-05-16 | R. Mark Graf | Director | A | — | — |
| 2025-05-16 | Gary Sender | Director | A | — | — |
| 2025-05-16 | Juan A. Sabater | Director | A | — | — |
| 2025-05-16 | Antonio J. Gracias | Director | A | — | — |
| 2025-05-16 | Ron M Philip | Director | A | — | — |
| 2025-05-09 | Kumar Budur | CHIEF MEDICAL OFFICER | MIXED | — | — |
| 2025-04-16 | Adam H. Zaeske | CHIEF COMMERCIAL OFFICER | A | — | — |
| 2025-04-04 | Ron M Philip | Director | A | — | — |
| 2025-04-03 | Sandip Kapadia | CHIEF FINANCIAL OFFICER | Sell | — | — |
| 2025-04-01 | Sandip Kapadia | CHIEF FINANCIAL OFFICER | MIXED | — | — |
| 2025-03-05 | Jeffrey Dierks | CHIEF COMMERCIAL OFFICER | MIXED | — | — |
| 2025-01-28 | Jeffrey M. Dayno | PRESIDENT, CEO | MIXED | — | — |
| 2025-01-28 | Kumar Budur | CHIEF MEDICAL OFFICER | MIXED | — | — |
| 2025-01-28 | Sandip Kapadia | CHIEF FINANCIAL OFFICER | MIXED | — | — |
| 2025-01-28 | Jeffrey Dierks | CHIEF COMMERCIAL OFFICER | MIXED | — | — |
| 2025-01-28 | Andrew Serafin | CHIEF STRATEGY OFFICER | MIXED | — | — |
| 2025-01-23 | Jeffrey M. Dayno | PRESIDENT, CEO | MIXED | — | — |
| 2025-01-23 | Sandip Kapadia | CHIEF FINANCIAL OFFICER | MIXED | — | — |
| 2025-01-21 | Jeffrey Dierks | CHIEF COMMERCIAL OFFICER | MIXED | — | — |
| 2025-01-16 | Jeffrey Dierks | CHIEF COMMERCIAL OFFICER | MIXED | — | — |
| 2025-01-15 | Jeffrey Dierks | CHIEF COMMERCIAL OFFICER | MIXED | — | — |
| 2024-11-05 | Marshman Fund Trust II | 10%+ Owner | Sell | — | — |
| 2024-11-05 | Valor IV Pharma Holdings, LLC | 10%+ Owner | Sell | — | — |
| 2024-10-31 | Jeffrey Dierks | CHIEF COMMERCIAL OFFICER | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 11,218,033 | — |
| — | 10%+ Owner | 6,618,033 | — |
| — | 10%+ Owner | 6,051,120 | — |
| — | 10%+ Owner | 3,754,973 | — |
| — | Director | 2,571,024 | — |
| — | Director | 2,154,393 | — |
| — | Director | 251,922 | — |
| — | 10%+ Owner | 38,275 | — |
| — | CHIEF MEDICAL OFFICER | 32,997 | — |
| — | CHIEF FINANCIAL OFFICER | 24,521 | — |
| — | PRESIDENT, CEO | 13,000 | — |
| — | CHIEF COMMERCIAL OFFICER | 4,869 | — |
| — | CHIEF COMMERCIAL OFFICER | 4,327 | — |
| — | CHIEF STRATEGY OFFICER | 2,500 | — |
| — | PRESIDENT, CEO | 909 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the HRMY quote page; the site-wide leaderboard is on the insider transactions hub.